Flynn Pharma

Flynn Pharma focuses on the acquisition, development and commercialisation of proprietary products for the secondary healthcare and related markets. Flynn's goal is to be the foremost European provider of specialty products in these targeted and underserved therapeutic categories. Flynn has been structured and financed to pursue a rapid growth strategy in these sectors, offering superior service for our customers and value for our shareholders. Our focus at Flynn Pharma is on prescription pharmaceutical products. Under-promoted brands from other pharmaceutical companies, who often have numerous products that are too small for them, or are no longer of strategic importance. In-licensing of late stage development products from R&D companies in specialist areas.
Company Growth (employees)
Type
Private
HQ
Stevenage, GB
Founded
1994
Size (employees)
29 (est)-3%
Flynn Pharma was founded in 1994 and is headquartered in Stevenage, GB

Flynn Pharma Office Locations

Flynn Pharma has an office in Stevenage
Stevenage, GB (HQ)
Primett Rd

Flynn Pharma Data and Metrics

Summary Metrics

Founding Date

1994

Flynn Pharma Financial Metrics

Flynn Pharma's revenue was reported to be £51.6 m in FY, 2016 which is a 3% increase from the previous period.
GBP

Revenue (FY, 2016)

51.6 m

Revenue growth (FY, 2015 - FY, 2016), %

3%

Gross profit (FY, 2016)

23.6 m

Gross profit margin (FY, 2016), %

46%
GBPFY, 2014FY, 2015FY, 2016

Revenue

54.1 m49.9 m51.6 m

Revenue growth, %

(8%)3%

Cost of goods sold

31.7 m27.7 m28.1 m

Gross profit

22.4 m22.2 m23.6 m

Gross profit Margin, %

41%44%46%

Operating expense total

11 m9.5 m11.1 m

Traffic Overview of Flynn Pharma

Flynn Pharma News and Updates

Drug firms ‘put lives of cancer patients at risk’ as out-of-patent prices are inflated

Research shows price of 14 treatments that should cost pennies has risen by up to 1,000%Drug companies have been accused of profiteering by raising the prices of out-of-patent cancer medicines that cost just pence to make, inflating the bills of the cash-strapped NHS by hundreds of millions of pound…

Watchdog accuses Actavis of hiking price of lifesaving drug by 12,000%

Pharmaceutical firm challenged over rise in cost of hydrocortisone tablets from 70p to £88 per tablet, costing NHS tens of millions extra each yearPharmaceutical company Actavis is facing accusations from the competition watchdog that it hiked the price of life-saving hydrocortisone tablets by more …

CEO Daily: Wednesday, 7th December

CEO Daily

Britain Just Fined Pfizer a Record $107 Million Over a Huge Drug Price Hike

The price of an epilepsy drug rose by as much as 2,600%.
Show more

Flynn Pharma Company Life and Culture

You may also be interested in